Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy

被引：1
|
作者：
Heming, Michael
Wiendl, Heinz [1 ]
机构：
[1] Univ Munster, Dept Neurol, D-48149 Munster, Germany
来源：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 2023年 / 120卷 / 06期
关键词：
T-CELLS; TERIFLUNOMIDE; OCRELIZUMAB;
D O I：
10.1073/pnas.2221544120
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
    Bar-Or, Amit
    O'Brien, Susan M.
    Sweeney, Michael L.
    Fox, Edward J.
    Cohen, Jeffrey A.
    CNS DRUGS, 2021, 35 (09) : 985 - 997
  • [42] Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
    Amit Bar-Or
    Susan M. O’Brien
    Michael L. Sweeney
    Edward J. Fox
    Jeffrey A. Cohen
    CNS Drugs, 2021, 35 : 985 - 997
  • [43] Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review
    Etemadifar, Masoud
    Nouri, Hosein
    Sedaghat, Nahad
    Ramezani, Aryana
    Kargaran, Parisa K.
    Salari, Mehri
    Kaveyee, Hasan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [44] Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy
    Korte, W
    Jost, C
    Cogliatti, S
    Hess, U
    Cerny, T
    ANNALS OF ONCOLOGY, 1999, 10 (10) : 1249 - 1250
  • [45] Immunological Response to COVID-19 Vaccine Boosters in Multiple Sclerosis Patients Treated with anti-CD20 Therapy
    De Oliveira, Antonia
    Lei, Joyce
    Liu, Jiayuan
    Roche, Morgan
    Lin, Jerry
    Alfonso, Roberto
    Sadiq, Saud
    NEUROLOGY, 2023, 100 (17)
  • [46] BLOCKING B-CELLS (ANTI-CD20/ANTI-CD20)
    Isenberg, David A.
    RHEUMATOLOGY, 2015, 54 : 1 - 1
  • [47] Influence of Body Mass Index on B Lymphocyte Repopulation in Multiple Sclerosis Patients Treated with Anti-CD20 Therapy
    Loeffler, Jacob
    Han, May
    NEUROLOGY, 2023, 100 (17)
  • [48] Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes"
    Rolfes, Leoni
    Meuth, Sven G.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 691 - 693
  • [49] Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary
    Gratch, Daniel
    Zhovtis Ryerson, Lana
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 695 - 696
  • [50] Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review
    Brown, Justin D.
    Muston, Benjamin T.
    Massey, Jennifer
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 86
12345